January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to ...